Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling

Molecular Immunology

Volumn 45, Issue 9, 2008, Pages 2651-2659

  James, Eddie A ^a   Moustakas, Antonis K ^c   Berger, DeAnna ^a   Huston, Laurie ^a   Papadopoulos, George K ^d   Kwok, William W ^a,b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c IONIAN UNIVERSITY   (Greece)

^d Faculty of Agricultural Technology   (Greece)

Author keywords

Binding assay; Class II MHC; HLA DR14; Peptide motif; Structural modeling

Indexed keywords

ALANYLSERYLALANYLGLYCYLGLUTAMINYLISOLEUCYLSERYLISOLEUCYL GLUTAMINYLPROLYLTHREONYLPHENYLALANYLSERYLVALYLGLUTAMINYLARGINYLASPARAGINYL LEUCYLPROLYLPHENYLALANINE; ARGINYLGLUTAMINYLLEUCYLPROLYLASPARAGINYLLEUCYLLEUCYLARGINYLGLYCYL TYROSYLGLUTAMYLARGINYLISOLEUCYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYL ASPARAGINYLVALINE; ARGINYLGLYCYLISOLEUCYLLEUCYLLEUCYLPROLYLGLUTAMINYLLYSYLVALYL TRYPTOPHYLCYSTEINYLALANYLSERYLGLYCYLARGINYLSERYLLYSYLVALYLISOLEUCYLLYSINE; ARGINYLISOLEUCYLARGINYLLEUCYLALANYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLARGINYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLGLUTAMINYLASPARAGINYL HISTIDYLASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLHISTIDYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLLEUCYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLMETHIONYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLPROLYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLSERYLASPARAGINYLARGINYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLSERYLASPARAGINYLLEUCYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLSERYLASPARAGINYLPROLYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLISOLEUCYLARGINYLLEUCYLTYROSYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLLEUCYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYLASPARAGINYLVALYL ISOLEUCYLASPARAGINE; ARGINYLMETHIONYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLPHENYLALANYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYL ASPARAGINYLVALYLISOLEUCYLASPARAGINE; ARGINYLTYROSYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYLASPARAGINYLVALYL ISOLEUCYLASPARAGINE; ARGINYLVALYLARGINYLLEUCYLSERYLASPARAGINYLHISTIDYLASPARAGINYLVALYL ISOLEUCYLASPARAGINE; EPITOPE; GLUTAMINYLISOLEUCYLGLUTAMYLVALYLTHREONYLASPARAGINYLALANYLTHREONYL GLUTAMYLLEUCYLVALYLGLUTAMINYLSERYLSERYLSERYLTHREONYLGLYCYLARGINYLISOLEUCYL CYSTEINE; GLUTAMINYLLEUCYLSERYLSERYLVALYLSERYLSERYLPHENYLALANYLGLUTAMYLARGINYL PHENYLALANYLGLUTAMYLISOLEUCYLPHENYLALANYLPROLYLLYSYLGLUTAMYLSERYLSERYLTRYPTOPHAN; GLUTAMINYLVALYLARGINYLGLUTAMYLSERYLARGINYLASPARAGINYLPROLYLGLYCYL ASPARAGINYLALANYLGLUTAMYLPHENYLALANYLGLUTAMYLASPARTYLLEUCYLTHREONYL PHENYLALANYLLEUCYLALANINE; GLUTAMYLHISTIDYLALANYLLYSYLALANYLISOLEUCYLGLYCYLASPARAGINYLCYSTEINYL PROLYLISOLEUCYLTRYPTOPHYLVALYLLYSYLTHREONYLPROLYLLEUCYLLYSYLLEUCYLALANINE; GLYCYLASPARAGINYLLEUCYLISOLEUCYLALANYLPROLYLARGINYLGLYCYLTYROSYL PHENYLALANYLLYSYLISOLEUCYLARGINYLSERYLGLYCYLLYSYLSERYLSERYLISOLEUCYLMETHIONINE; GLYCYLTYROSYLGLUTAMYLARGINYLISOLEUCYLARGINYLLEUCYLSERYLASPARAGINYL HISTIDYLASPARAGINYLVALYLISOLEUCYLASPARAGINYLALANYLGLUTAMYLLYSYLALANYL PROLYLGLYCINE; GLYCYLVALYLGLYCYLTHREONYLMETHIONYLVALYLMETHIONYLGLUTAMYLLEUCYLVALYL ARGINYLMETHIONYLISOLEUCYLLYSYLARGINYLGLYCYLISOLEUCYLASPARAGINYLASPARTYLARGININE; LYSYLTHREONYLGLYCYLTHREONYLISOLEUCYLTHREONYLTYROSYLGLUTAMINYLARGINYL GLYCYLISOLEUCYLLEUCYLLEUCYLPROLYLGLUTAMINYLLYSYLVALYLTRYPTOPHYLCYSTEINYLALANINE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG IDENTIFICATION; PRIORITY JOURNAL; PROTEIN MOTIF;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; BINDING SITES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HLA-DR ANTIGENS; HUMANS; INFLUENZA B VIRUS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 40849145701     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.12.013     Document Type: Article

References (26)

1. Bhattacharya T., Daniels M., Heckerman D., Foley B., Frahm N., Kadie C., Carlson J., Yusim K., McMahon B., Gaschen B., Mallal S., Mullins J.I., Nickle D.C., Herbeck J., Rousseau C., Learn G.H., Miura T., Brander C., Walker B., and Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315 (2007) 1583-1586
2. Bondinas G.P., Moustakas A.K., and Papadopoulosm G.K. The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. Immunogenetics 59 (2007) 539-553
3. Chua-Intra B., Peerapakorn S., Davey N., Jurcevic S., Busson M., Vordermeier H.M., Pirayavaraporn C., and Ivanyi J. T-cell recognition of mycobacterial GroES peptides in Thai leprosy patients and contacts. Infect. Immun. 66 (1998) 4903-4909
4. Davenport M.P., Quinn C.L., Chicz R.M., Green B.N., Willis A.C., Lane W.S., Bell J.I., and Hill A.V. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 6567-6571
5. Ettinger R.A., and Kwok W.W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J. Immunol. 160 (1998) 2365-2373
6. Ettinger R.A., Papadopoulos G.K., Moustakas A.K., Nepom G.T., and Kwok W.W. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1*06 alleles. J. Immunol. 176 (2006) 1988-1998
7. Falk K., Rötzschke O., Stevanović S., Jung G., and Rammensee H.G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39 (1994) 230-242
8. Fremont D.H., Hendrickson W.A., Marrack P., and Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science 272 (1996) 1001-1004
9. Fujita H., Senju S., Yokomizo H., Saya H., Ogawa M., Matsushita S., and Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self-peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol. 28 (1998) 305-316
10. Geluk A., van Meijgaarden K.E., Southwood S., Oseroff C., Drijfhout J.W., de Vries R.R., Ottenhoff T.H., and Sette A. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152 (1994) 5742-5748
11. Ghosh P., Amaya M., Mellins E., and Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378 (1995) 457-462
12. Guttinger M., Romagnoli P., Vandel L., Meloen R., Takacs B., Pink J.R., and Sinigaglia F. HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int. Immunol. 3 (1991) 899-906
13. Harris P.E., Maffei A., Colovai A.I., Kinne J., Tugulea S., and Suciu-Foca N. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood 87 (1996) 5104-5112
14. Jee S.H., Tsai T.F., Tsai W.L., Liaw S.H., Chang C.H., and Hu C.Y. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br. J. Dermatol. 139 (1998) 978-983
15. Kwok W.W., Gebe J.A., Liu A., Agar S., Ptacek N., Hammer J., Koelle D.M., and Nepom G.T. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol. 22 (2001) 583-588
16. Neumann F., Wagner C., Preuss K.D., Kubuschok B., Schormann C., Stevanovic S., and Pfreundschuh M. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood 106 (2005) 3105-3113
17. Novak E.J., Liu A.W., Nepom G.T., and Kwok W.W. MHC class II tetramers identify peptide-specific human CD4 (+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104 (1999) R63-R67
18. Novak E.J., Liu A.W., Gebe J.A., Falk B.A., Nepom G.T., Koelle D.M., and Kwok W.W. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J. Immunol. 166 (2001) 6665-6670
19. Redondo M.J., Kawasaki E., Mulgrew C.L., Noble J.A., Erlich H.A., Freed B.M., Lie B.A., Thorsby E., Eisenbarth G.S., Undlien D.E., and Ronningen K.S. DR- and DQ-associated protection from type 1A diabetes: comparison of DRB1*1401 and DQA1*0102-DQB1*0602*. J. Clin. Endocrinol. Metab. 85 (2000) 3793-3797
20. Reichstetter S., Papadopoulos G.K., Moustakas A.K., Swanson E., Liu A.W., Beheray S., Ettinger R.A., Nepom G.T., and Kwok W.W. Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T-cell clones. Hum. Immunol. 63 (2002) 185-193
21. Sette A., Sidney J., Oseroff C., del Guercio M.F., Southwood S., Arrhenius T., Powell M.F., Colón S.M., Gaeta F.C., and Grey H.M. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151 (1993) 3163-3170
22. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., and Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 (1994) 215-221
23. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., and Hammer J. Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17 (1999) 555-561
24. Taylor G.S., Long H.M., Haigh T.A., Larsen M., Brooks J., and Rickinson A.B. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 177 (2006) 3746-3756
25. Verreck F.A., van de Poel A., Drijfhout J.W., Amons R., Coligan J.E., and Konig F. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics 43 (1996) 392-397
26. Wucherpfennig K.W., Sette A., Southwood S., Oseroff C., Matsui M., Strominger J.L., and Hafler D.A. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179 (1994) 279-290